Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Fetal Stem Mesenchymal Cells for Bronchopulmonary Dysplasia in Preterm Infants
NCT06270199Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2 trial in bronchopulmonary dysplasia (BPD) (3 arms). Primary endpoints: Security of MSC therapy at 24 months and Feasibility variable at 24 months. Started Jan 2024; status: recruiting.
02
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT06270199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270199.